MLYS - Mineralys Therapeutics Inc
IEX Last Trade
12.44
-0.130 -1.045%
Share volume: 106,900
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$12.57
-0.13
-1.03%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
6.89%
1 Month
-0.72%
3 Months
-0.08%
6 Months
-15.81%
1 Year
-3.42%
2 Year
-32.70%
Key data
Stock price
$12.44
DAY RANGE
$12.16 - N/A
52 WEEK RANGE
$5.85 - $16.91
52 WEEK CHANGE
-$0.04
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO:
Region: US
Website:
Employees: 12
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website:
Employees: 12
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
at mineralys therapeutics we aim to redefine hypertension diagnosis, management and treatment. we are driven to break the “trial and failure” approach to hypertension management and bring a personalized approach to the management of hypertension.
Recent news